convalescent plasma

convalescent plasma
Name	Convalescent plasma
Specialty	Hematology; Transfusion medicine; Infectious diseases
Uses	Passive immunotherapy for infectious diseases
Risks	Transfusion reactions; alloimmunization; infectious transmission
Legal	Regulated by national blood authorities

convalescent plasma is plasma collected from individuals who have recovered from a specific infectious disease and developed antibodies against the causative pathogen. It has been used as a form of passive immunotherapy in outbreaks and epidemics, drawing attention during events such as the 1918 influenza pandemic and the COVID-19 pandemic. Practice has evolved through intersections with transfusion systems like the American Red Cross, regulatory bodies such as the United States Food and Drug Administration, and research networks including the World Health Organization.

Definition and historical background

Convalescent plasma originated in early twentieth‑century responses to viral and bacterial epidemics, with early applications linked to clinicians and institutions active during the Spanish flu era and later refined through work at centers like the Rockefeller Institute and hospitals involved in the Second World War. Later twentieth‑century uses occurred during outbreaks managed by agencies such as the Centers for Disease Control and Prevention and research by investigators affiliated with universities like Harvard University, Johns Hopkins University, and University of Oxford. During the twenty‑first century, high‑profile deployments occurred for outbreaks of Ebola virus disease managed by teams from Médecins Sans Frontières and multinational consortia, and for the global response to SARS-CoV-2 supported by networks including the National Institutes of Health and the European Medicines Agency.

Collection, processing, and quality control

Collection follows standards established by blood services such as the American Red Cross, NHS Blood and Transplant, and national transfusion authorities in countries like Canada and Australia. Donor eligibility criteria are often determined by agencies such as the FDA and Health Canada, and draw on pathogen testing platforms developed at institutions like Roche Diagnostics and Abbott Laboratories. Processing includes plasmapheresis performed with equipment from manufacturers like Terumo or Fresenius Kabi, and laboratory assays for antibody quantification developed by groups at Imperial College London and the Pasteur Institute. Quality control protocols mirror those for standard plasma, incorporating nucleic acid testing used by laboratories partnering with consortia such as the Global Alliance for Vaccines and Immunization and storage standards referenced by the World Health Organization.

Mechanism of action and immunology

Therapeutic effects derive primarily from pathogen‑specific antibodies—principally neutralizing immunoglobulins—generated by donors after infection, with mechanistic insights contributed by research teams at institutions such as the Max Planck Society, Salk Institute, and Massachusetts Institute of Technology. Antibody functions include neutralization characterized in studies from the Pasteur Institute, opsonization described in work from Rockefeller University, and Fc receptor‑mediated effector functions examined by groups at Stanford University and the Karolinska Institute. Immunological assessments often use assays standardized by laboratories at Oxford University and the National Institute for Biological Standards and Control, and are interpreted in the context of underlying host responses defined in immunology texts from investigators like Anthony Fauci's teams at the National Institute of Allergy and Infectious Diseases.

Clinical uses and evidence by disease

Historical and modern evidence spans diverse pathogens; notable examples include therapeutic trials during 1918 influenza pandemic cohorts, case series from the Ebola virus epidemic in West Africa led by multinational clinical groups, and randomized trials for COVID-19 coordinated by networks including the NIH and regional agencies like the European Centre for Disease Prevention and Control. Evidence quality ranges from observational data gathered by hospitals such as Mayo Clinic and Mount Sinai Hospital to randomized controlled trials conducted at centers like University of Pennsylvania and University College London. Disease‑specific guidance has been informed by task forces convened by entities including the Infectious Diseases Society of America and panels at the World Health Organization, which have evaluated outcomes for influenza, severe acute respiratory syndromes, viral hemorrhagic fevers, and other emergent infections.

Safety, risks, and adverse effects

Safety profiles parallel those of standard plasma transfusion and have been characterized by hemovigilance systems run by organizations such as the UK Blood Transfusion Service and the Hemovigilance Program of Canada. Documented risks include transfusion‑related acute lung injury investigated by investigators at Beth Israel Deaconess Medical Center, transfusion‑associated circulatory overload described in clinical guidelines from American Association of Blood Banks, allergic reactions catalogued by the World Health Organization, and theoretical risks of antibody‑dependent enhancement discussed in reviews authored by groups at Johns Hopkins University and Imperial College London. Infectious disease transmission risks are minimized by screening protocols developed with diagnostic manufacturers and oversight from regulatory bodies including the FDA and the European Medicines Agency.

Regulatory, ethical, and access considerations

Regulatory frameworks have been shaped by precedents from the FDA emergency use programs, licensure pathways managed by the European Medicines Agency, and national policies from ministries of health in jurisdictions such as India and Brazil. Ethical debates involve equitable allocation discussed by bioethics centers at Harvard University and Georgetown University, consent practices reviewed in committees at the Nuffield Council on Bioethics, and intellectual property and data sharing considered in forums like the World Health Assembly. Access challenges engage blood services including the American Red Cross and international relief organizations such as UNICEF and Médecins Sans Frontières, which negotiate logistics in low‑resource settings and during humanitarian emergencies like the West African Ebola epidemic.

Category:Blood products